

BeOne Medicines (ONC US)

Near-term readouts to validate novel pipeline assets

BeOne delivered robust 1Q26 product sales growth and improving profitability, prompting management to raise FY26 guidance. We continue to see significant upside for Brukinsa's global BTK market share expansion. Furthermore, multiple near-term clinical data readouts present compelling catalysts for further valuation upside. We maintain BUY rating on BeOne with a TP of US\$392.43.

- Strong 1Q26 sales momentum.** BeOne reported 1Q26 total revenue of US\$1.51bn (+35% YoY), representing 28% of our previous FY26 estimate and exceeding our expectations. This robust growth was primarily driven by Brukinsa, which generated US\$1.10bn in 1Q26 sales (+38% YoY). Brukinsa retains its position as the top-selling global BTK inhibitor by revenue, underpinned by its leadership in new patient starts for US CLL and sustained EU expansion fueled by improving reimbursement coverage. We anticipate continued market share gains of Brukinsa and project FY26E Brukinsa sales of US\$4.67bn (+19% YoY).
- Profitability continues to improve.** BeOne sustained its profitability trajectory in 1Q26, delivering GAAP net income of US\$277mn, underpinned by robust top-line growth and enhanced operating leverage. Non-GAAP net income has demonstrated consecutive quarter-over-quarter expansion since 1Q25, reaching US\$414mn in 1Q26. Operating efficiency also strengthened: the SG&A-to-sales ratio declined to 37.3% (vs. 39.4% in FY25), and the R&D-to-sales ratio moderated to 36.4% (vs. 40.6% in FY25). Prompted by this strong 1Q26 performance, management raised its FY26 revenue guidance to US\$6.3–6.5bn (from US\$6.2–6.4bn) and GAAP operating profit guidance to US\$750–850mn (from US\$700–800mn).
- Continued enhancement of the hematology franchise.** Sonrotoclax (Bcl-2) is positioned for potential FDA approval in 2Q26 for BTKi-treated MCL, following its launch in China. BeOne also plans to advance Sonrotoclax into a Ph3 study for 2L+ t(11;14) MM in 2H26. Furthermore, we anticipate uMRD data from the Ph3 Sonrotoclax + Brukinsa trial in 1L CLL in 3Q26, as nearly all patients have recently completed the fixed-duration treatment. We also expect a US NDA submission for the BTK CDAC in R/R CLL in 2H26.
- Multiple near-term solid tumor catalysts.** We think multiple upcoming clinical milestones could unlock further valuation upside. Ph1 data for BGB-43395 (CDK4 inhibitor) in 1L HR+/HER2- breast cancer (BC) at the upcoming ASCO meeting should drive near-term sentiment. As a potentially best-in-class CDK4-selective agent with a differentiated hematological toxicity profile, BGB-43395 is slated for a global Ph3 trial in 1L BC. Additionally, 1H26 will feature ASCO data readouts for the GPC3/4-1BB bsAb and B7-H4 ADC, followed by clinical updates for the PRMT5i and CEA ADC in 2H26. The GPC3/4-1BB bsAb is currently enrolling a potential pivotal study in late-line HCC, alongside the ongoing study in 1L HCC. The PD-1/VEGF-A/CTLA-4 tsAb is also expected to enter a Ph1 study shortly.
- Maintain BUY.** We expect BeOne to deliver robust FY26 sales growth and profitability, further supported by a catalyst-rich R&D pipeline. We maintain our DCF-derived target price unchanged at US\$392.43 (WACC: 9.64%, terminal growth rate: 3.5%).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (US\$ mn)	3,810	5,343	6,421	7,378	8,233
Net profit (US\$ mn)	(644.8)	286.9	752.4	1,329.1	1,932.6
EPS (Reported) (US\$)	(6.12)	2.63	6.35	11.22	16.31
P/S (x)	9.7	6.9	5.8	5.0	4.5
P/E (x)	ns	119.1	49.3	27.9	19.2

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	US\$392.43
Up/Downside	25.2%
Current Price	US\$313.32

China Healthcare

Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288

andywang@cmbi.com.hk

Stock Data

Mkt Cap (US\$ mn)	37,132.7
Avg 3 mths t/o (US\$ mn)	39.5
52w High/Low (US\$)	377.47/219.95
Total Issued Shares (mn)	118.5

Source: FactSet

Shareholding Structure

Amgen	17.1%
Baker Bros	8.0%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	3.1%	-12.1%
3-mth	-11.5%	-21.1%
6-mth	-2.1%	-12.8%


Source: FactSet

12-mth Price Performance




Source: FactSet

Figure 1: Quarterly product sales of BeOne




Source: Company data, CMBIGM

Figure 2: Brukinsa quarterly sales



Source: Company data, CMBIGM

Figure 3: Tiselizumab quarterly sales



Source: Company data, CMBIGM

Figure 4: Risk-adjusted DCF valuation

DCF valuation (US\$ mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	805	1,516	2,205	2,552	3,187	3,874	4,464	4,668	4,681	4,663
Tax rate	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	684	1,288	1,874	2,169	2,709	3,293	3,794	3,968	3,979	3,963
+ D&A	146	151	151	150	146	143	139	136	133	131
- Change in working capital	-53	-153	-135	11	-189	-136	-116	-40	-6	12
- Capex	-200	-200	-150	-150	-100	-100	-100	-100	-100	-100
FCFF	577	1,086	1,740	2,181	2,567	3,200	3,718	3,964	4,006	4,006
Terminal value										67,535
PV of enterprise (US\$ mn)	41,824									
Net debt (US\$ mn)	-4,685									
Equity value (US\$ mn)	46,509									
No. of ADS (mn)	119									
DCF per ADS (US\$)	392.43									
Terminal growth rate	3.5%									
WACC	9.64%									
Cost of equity	13.0%									
Cost of debt	4.0%									
Equity beta	1.00									
Risk-free rate	3.0%									
Market risk premium	10.0%									
Target debt to asset ratio	35.0%									
Effective corporate tax rate	15.0%									

Source: CMBIGM estimates

Figure 5: Sensitivity analysis (US\$)

Terminal growth rate	WACC				
	8.64%	9.14%	9.64%	10.14%	10.64%
4.5%	545.34	486.52	439.22	400.37	367.90
4.0%	503.60	454.26	413.75	379.91	351.22
3.5%	469.98	427.73	392.43	362.52	336.87
3.0%	442.32	405.51	374.32	347.57	324.39
2.5%	419.17	386.64	358.75	334.58	313.45

Source: CMBIGM estimates

Figure 6: CMBIGM estimates vs consensus

US\$ mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,421	7,378	8,233	6,364	7,315	8,205	1%	1%	0%
Gross Profit	5,617	6,477	7,251	5,559	6,410	7,234	1%	1%	0%
Operating Profit	805	1,516	2,205	744	1,154	1,636	8%	31%	35%
Net profit	752	1,329	1,933	637	1,093	1,460	18%	22%	32%
EPS (US\$)	6.35	11.22	16.31	5.78	10.15	13.16	10%	10%	24%
Gross Margin	87.49%	87.78%	88.08%	87.35%	87.63%	88.16%	+0.14 ppt	+0.15 ppt	-0.08 ppt
Operating Margin	12.54%	20.54%	26.78%	11.69%	15.78%	19.94%	+0.84 ppt	+4.77 ppt	+6.85 ppt
Net Margin	11.72%	18.01%	23.48%	10.01%	14.94%	17.79%	+1.71 ppt	+3.07 ppt	+5.68 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Figure 7: CMBIGM estimates: New vs Old

US\$ mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	6,421	7,378	8,233	6,320	7,249	8,135	2%	2%	1%
Gross Profit	5,617	6,477	7,251	5,539	6,367	7,161	1%	2%	1%
Operating Profit	805	1,516	2,205	725	1,419	1,930	11%	7%	14%
Net profit	752	1,329	1,933	684	1,246	1,696	10%	7%	14%
EPS (US\$)	6.35	11.22	16.31	5.78	10.51	14.31	10%	7%	14%
Gross Margin	87.49%	87.78%	88.08%	87.64%	87.83%	88.03%	-0.15 ppt	-0.05 ppt	+0.05 ppt
Operating Margin	12.54%	20.54%	26.78%	11.48%	19.57%	23.72%	+1.06 ppt	+0.97 ppt	+3.06 ppt
Net Margin	11.72%	18.01%	23.48%	10.83%	17.19%	20.85%	+0.89 ppt	+0.83 ppt	+2.62 ppt

Source: Company data, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Revenue	2,459	3,810	5,343	6,421	7,378	8,233
Cost of goods sold	(380)	(594)	(669)	(804)	(901)	(981)
Gross profit	2,079	3,216	4,674	5,617	6,477	7,251
Operating expenses	(3,287)	(3,784)	(4,227)	(4,812)	(4,961)	(5,046)
SG&A expense	(1,505)	(1,831)	(2,081)	(2,463)	(2,553)	(2,605)
R&D expense	(1,779)	(1,953)	(2,146)	(2,349)	(2,407)	(2,442)
Others	(4)	0	0	0	0	0
Other income	382	35	(30)	80	48	69
Pre-tax profit	(826)	(533)	417	885	1,564	2,274
Income tax	(56)	(112)	(130)	(133)	(235)	(341)
Minority interest	0	0	0	0	0	0
Net profit	(882)	(645)	287	752	1,329	1,933
Adjusted net profit	(882)	(645)	287	752	1,329	1,933
BALANCE SHEET						
YE 31 Dec (US\$ mn)						
Current assets	4,203	3,992	6,234	7,284	8,926	11,407
Cash & equivalents	3,172	2,627	4,548	5,504	6,942	9,251
Account receivables	358	676	865	916	1,052	1,174
Inventories	416	495	608	652	719	769
Financial assets at FVTPL	3	0	0	0	0	0
Other current assets	255	193	213	213	213	213
Non-current assets	1,602	1,929	1,955	2,009	2,058	2,058
PP&E	1,324	1,578	1,642	1,695	1,745	1,744
Deferred income tax	0	0	0	0	0	0
Intangibles	57	51	63	63	63	63
Other non-current assets	221	300	251	251	251	251
Total assets	5,805	5,921	8,189	9,293	10,984	13,465
Current liabilities	1,810	2,215	1,829	1,870	1,921	1,958
Short-term borrowings	688	852	57	57	57	57
Account payables	315	405	479	520	571	608
Tax payable	23	26	42	42	42	42
Other current liabilities	784	932	1,251	1,251	1,251	1,251
Non-current liabilities	458	374	1,148	948	748	748
Long-term borrowings	198	166	962	762	562	562
Deferred income	0	0	0	0	0	0
Other non-current liabilities	260	207	186	186	186	186
Total liabilities	2,268	2,589	2,977	2,818	2,669	2,707
Share capital	11,599	12,088	12,759	13,270	13,781	14,292
Retained earnings	(7,962)	(8,607)	(8,320)	(7,567)	(6,238)	(4,306)
Other reserves	(99)	(149)	(78)	(78)	(78)	(78)
Total shareholders equity	3,537	3,332	4,361	5,624	7,464	9,908
Minority interest	0	0	0	0	0	0
Total equity and liabilities	5,805	5,921	8,189	9,293	10,984	13,465

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (US\$ mn)						
Operating						
Profit before taxation	(826)	(533)	417	885	1,564	2,274
Depreciation & amortization	88	172	142	146	151	151
Tax paid	(56)	(112)	(130)	(133)	(235)	(341)
Others	(363)	332	699	458	358	376
Net cash from operations	(1,157)	(141)	1,128	1,356	1,838	2,459
Investing						
Capital expenditure	(562)	(493)	(186)	(200)	(200)	(150)
Acquisition of subsidiaries/ investments	(17)	(22)	(12)	0	0	0
Net proceeds from disposal of short-term investments	673	3	3	0	0	0
Others	(34)	(36)	(82)	0	0	0
Net cash from investing	60	(548)	(276)	(200)	(200)	(150)
Financing						
Net borrowings	684	877	1,084	0	0	0
Proceeds from share issues	0	0	907	0	0	0
Others	(268)	(684)	(932)	(200)	(200)	0
Net cash from financing	416	193	1,059	(200)	(200)	0
Net change in cash						
Cash at the beginning of the year	3,875	3,186	2,639	4,548	5,504	6,942
Exchange difference	(8)	(52)	60	0	0	0
Cash at the end of the year	3,186	2,639	4,610	5,504	6,942	9,251
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	73.7%	55.0%	40.2%	20.2%	14.9%	11.6%
Gross profit	84.1%	54.7%	45.3%	20.2%	15.3%	12.0%
Net profit	na	na	na	162.2%	76.6%	45.4%
Adj. net profit	na	na	na	162.2%	76.6%	45.4%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	84.5%	84.4%	87.5%	87.5%	87.8%	88.1%
Adj. net profit margin	(35.9%)	(16.9%)	5.4%	11.7%	18.0%	23.5%
Return on equity (ROE)	(22.3%)	(18.8%)	7.5%	15.1%	20.3%	22.2%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.7)	(0.5)	(0.8)	(0.8)	(0.8)	(0.9)
Current ratio (x)	2.3	1.8	3.4	3.9	4.6	5.8
Receivable turnover days	39.4	49.5	52.6	52.6	52.6	52.6
Inventory turnover days	335.5	279.9	301.2	296.2	291.2	286.2
Payable turnover days	293.0	221.2	241.3	236.3	231.3	226.3
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	ns	ns	119.1	49.3	27.9	19.2
P/E (diluted)	ns	ns	123.9	49.3	27.9	19.2
P/B	120.2	128.7	101.9	85.8	64.7	48.7

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.